Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration.

Lee SM, Asress S, Hales CM, Gearing M, Vizcarra JC, Fournier CN, Gutman DA, Chin LS, Li L, Glass JD.

Brain Commun. 2019;1(1):fcz014. doi: 10.1093/braincomms/fcz014. Epub 2019 Sep 11.

2.

The gut microbiome and neuroinflammation in amyotrophic lateral sclerosis? Emerging clinical evidence.

Fournier CN, Houser M, Tansey MG, Glass JD, Hertzberg VS.

Neurobiol Dis. 2018 Oct 12:104300. doi: 10.1016/j.nbd.2018.10.007. [Epub ahead of print] Review. No abstract available.

PMID:
30321601
3.

Reader response: Pathologic Thr175 tau phosphorylation in CTE and CTE with ALS.

Glass JD, Fournier CN, Gearing M.

Neurology. 2018 Sep 18;91(12):578-579. doi: 10.1212/WNL.0000000000006192. No abstract available.

PMID:
30224504
4.

An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis.

Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):242-249. doi: 10.1080/21678421.2017.1421666. Epub 2018 Jan 8.

PMID:
29308669
5.

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L.

Sci Transl Med. 2017 Mar 29;9(383). pii: eaai7866. doi: 10.1126/scitranslmed.aai7866.

6.

Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.

Fournier CN, Murphy A, Loci L, Mitsumoto H, Lomen-Hoerth C, Kisanuki Y, Simmons Z, Maragakis NJ, McVey AL, Al-Lahham T, Heiman-Patterson TD, Andrews J, McDonnell E, Cudkowicz M, Atassi N.

J Clin Neuromuscul Dis. 2016 Mar;17(3):99-105. doi: 10.1097/CND.0000000000000102.

7.

Head injury does not alter disease progression or neuropathologic outcomes in ALS.

Fournier CN, Gearing M, Upadhyayula SR, Klein M, Glass JD.

Neurology. 2015 Apr 28;84(17):1788-95. doi: 10.1212/WNL.0000000000001522. Epub 2015 Apr 1.

8.

ANNA-1 (anti-Hu) associated sensory neuronopathy with malignant mixed mullerian tumor.

Fournier CN, Kalra A, Lachance DH, Zarwan C, Srinivasan J.

Muscle Nerve. 2013 May;47(5):776-7. doi: 10.1002/mus.23764. Epub 2013 Mar 27. No abstract available.

PMID:
23536385

Supplemental Content

Loading ...
Support Center